Taiwan National Health Scheme "In March"

20 February 1995

The director-general of Taiwan's Department of Health, B Zhang, has said the DoH's biggest project this year will be establishing the new Central health Insurance Bureau, which will enable the new universal health insurance system to take effect. While legislation to introduce the NT$5.1 billion ($193.5 million) program was due to be passed by the Legislative Yuan this month, Mr Zhang said it would take longer than that to set up the Bureau, and he expected the scheme to take effect in March.

Late last year the government had said it was determined to get the new system running in january, but problems have included a lack of consensus on insurance among health industry groups, local governing bodies and farmers' cooperatives, and also that Taiwan lacks enabling legislative infrastructure for a new agency to regulate health issues. This has prevented the Department from setting budgets for the new agency or recruiting staff.

Meantime, Taiwan had 32,101 pharmaceutical-related businesses in 1993, up 119 on 1992, says Department of Health data, published in Pharma Japan. 13,624 of these were drug traders, and of these there were 453 fewer marketers at 13,375, and manufacturers were down three to 249. Good Manufacturing Practice-conforming manufacturers fell by four to 22.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK





Today's issue

Company Spotlight